We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+11.15%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$457M
AUM Growth
+$26.6M
Cap. Flow
+$8.53M
Cap. Flow %
1.86%
Top 10 Hldgs %
38.17%
Holding
99
New
16
Increased
39
Reduced
27
Closed
17

Top Buys

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$16.5M
2
RGEN icon
Repligen
RGEN
+$7.52M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$6.71M
4
NVRO
NEVRO CORP.
NVRO
+$5.59M
5
DXCM icon
DexCom
DXCM
+$4.89M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$11.2M
2
VCEL icon
Vericel Corp
VCEL
+$5.11M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$4.72M
4
ARWR icon
Arrowhead Research
ARWR
+$4.65M
5
CDMO
Avid Bioservices, Inc. Common Stock
CDMO
+$4.27M

Sector Composition

Rank Sector Weight
1 Healthcare 95.62%
2 Technology 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOCL
51
EDAP TMS S.A.
FOCL
$183M
$2.46M 0.54%
346,926
-226,448
-39% -$1.64M
BCYC
52
Bicycle Therapeutics
BCYC
$289M
$2.45M 0.54%
80,839
+5,385
+7% +$163K
SIEN
53
DELISTED
Sientra, Inc.
SIEN
$2.4M 0.53%
+30,175
New +$2.14M
SDGR icon
54
Schrodinger
SDGR
$1.39B
$2.31M 0.51%
30,608
-9,845
-24% -$714K
BLRX
55
BioLineRX
BLRX
$11.7M
$2.06M 0.45%
18,351
+7,598
+71% +$893K
TRIL
56
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.05M 0.45%
211,385
+61,081
+41% +$575K
ONCT
57
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$1.97M 0.43%
20,769
-18,170
-47% -$2.16M
ALT icon
58
Altimmune
ALT
$593M
$1.97M 0.43%
+200,000
New +$2.73M
KDMN
59
DELISTED
Kadmon Holdings, Inc.
KDMN
$1.94M 0.42%
501,740
-322,735
-39% -$1.25M
ANIP icon
60
ANI Pharmaceuticals
ANIP
$1.71B
$1.94M 0.42%
+55,346
New +$1.88M
PHLT
61
DELISTED
Performant Healthcare Inc
PHLT
$1.86M 0.41%
497,334
-252,666
-34% -$719K
CSLT
62
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$1.78M 0.39%
677,734
+177,341
+35% +$330K
SCTL
63
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$1.78M 0.39%
770,833
+168,866
+28% +$429K
GYRE icon
64
Gyre Therapeutics
GYRE
$704M
$1.7M 0.37%
52,460
+244
+0.5% +$8.37K
SURF
65
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$1.7M 0.37%
228,267
-23,977
-10% -$185K
TELA icon
66
TELA Bio
TELA
$32.5M
$1.61M 0.35%
+100,000
New +$1.37M
FULC icon
67
Fulcrum Therapeutics
FULC
$285M
$1.53M 0.34%
146,389
+20,651
+16% +$209K
NTLA icon
68
Intellia Therapeutics
NTLA
$1.69B
$1.21M 0.27%
+7,500
New +$584K
TLMD
69
DELISTED
SOC Telemed, Inc. Class A Common Stock
TLMD
$1.18M 0.26%
208,121
+15,994
+8% +$106K
MTEM
70
DELISTED
Molecular Templates, Inc.
MTEM
$1.11M 0.24%
9,444
-1,611
-15% -$211K
VCEL icon
71
Vericel Corp
VCEL
$2.29B
$1.07M 0.23%
20,340
-89,660
-82% -$5.11M
FBRX icon
72
Forte Biosciences
FBRX
$1.57B
$1.06M 0.23%
1,256
+6
+0.5% +$5.41K
VERA icon
73
Vera Therapeutics
VERA
$2.17B
$1M 0.22%
+75,638
New +$1.18M
KRMD icon
74
KORU Medical Systems
KRMD
$154M
$932K 0.2%
201,256
-60,466
-23% -$237K
BCEL
75
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$857K 0.19%
100,628
-51,365
-34% -$526K
1 2
3
4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q2 2021 Portfolio in Review

As of Q2 2021, Parkman Healthcare Partners held 99 positions worth $457M, up 6.2% from $431M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Parkman Healthcare Partners's Q2 2021 filing shows 16 new, 39 increased, 27 reduced and 17 closed positions. Its largest new stake was Intuitive Surgical: 58,839 shares worth $18M. The largest sale was Amgen, an estimated $11.2M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 92% a quarter earlier, followed by Technology.

  • Parkman Healthcare Partners's largest Q2 2021 buy was Intuitive Surgical: 58,839 shares worth $18M.
  • Parkman Healthcare Partners added most to DexCom in Q2 2021, an estimated $4.89M increase.
  • Parkman Healthcare Partners's biggest Q2 2021 reduction was Vericel Corp, cutting an estimated $5.11M.
  • Parkman Healthcare Partners fully exited Amgen in Q2 2021, selling an estimated $11.2M.
  • Parkman Healthcare Partners's ten largest holdings make up 38% of its $457M portfolio in Q2 2021.
  • Parkman Healthcare Partners opened 16 new positions and closed 17 in Q2 2021.
  • Parkman Healthcare Partners's portfolio value rose 6.2% quarter-over-quarter to $457M.

Based on Parkman Healthcare Partners's 13F filing for Q2 2021, filed 13 Aug 2021.